1) Imai N, Endo N, Shobugawa Y, et al. Incidence of four major types of osteoporotic fragility fractures among elderly individuals in Sado, Japan, in 2015. J Bone Miner Metab 2019;37(3):484-90.
2) 大月道夫.Cushing症候群・副腎性subclinical Cushing症候群の診断と治療.日内会誌2018;107(4):674-80.
3) Miyazato M, Ishidoya S, Satoh F, et al. Surgical outcomes of laparoscopic adrenalectomy for patients with Cushing's and subclinical Cushing's syndrome:a single center experience. Int Urol Nephrol 2011;43(4):975-81.
4) 大森就子,伊東絵美奈,野村 馨・他.多発性脊椎圧迫骨折を伴った若年クッシング症候群の1例:重症骨粗鬆症の病態と治療経過について.ホルモンと臨床2000;48(8):759-63.
5) 熊谷康佑,今井晋二,菊地克久・他.脊椎多発骨折を伴う骨粗鬆症により診断されたクッシング症候群の1例.中部整災誌2007;50(3):505-6.
6) 服部沙耶,眞弓大輝,近藤あむろ・他.若年での骨粗鬆症により脆弱性骨折に至って診断されたクッシング症候群の1例.日内分泌会誌2019;95(3):970.
7) Chiodini I, Carnevale V, Torlontano M, et al. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess:study in eumenorrheic patients with Cushing's syndrome. J Clin Endocrinol Metab 1998;83(6):1863-7.
8) Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis:pathophysiology and therapy. Osteoporos Int 2007;18(10):1319-28.
9) Delgado-Calle J, Sato AY, Bellido T. Role and mechanism of action of sclerostin in bone. Bone 2017;96:29-37.
10) Yao W, Dai W, Jiang L, et al. Sclerostin-antibody treatment of glucocorticoid-induced osteoporosis maintained bone mass and strength. Osteoporos Int 2016;27(1):283-94.
11) Braun LT, Fazel J, Zopp S, et al. The effect of biochemical remission on bone metabolism in Cushing's syndrome:a 2-year follow-up study. J Bone Miner Res 2020;35(9):1711-7.
12) Gennari L, Rotatori S, Bianciardi S, et al. Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother 2016;17(8):1141-52.